SBI HEALTHCARE OPPORTUNITIES FUND

A Sectoral/Thematic Fund scheme from SBI Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF200K01UP2).

NAV ₹623.7185 on 16 November 2026.

Expense ratio

Total expense ratio 1.00% a year for the Direct · Growth plan, as AMFI published it on 28 October 2026: base expense ratio 0.73%, brokerage 0.04%, transaction costs 0.00%, statutory levies including GST 0.23%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year26.1%13.9%-10.2%1.381.49
3 years25.4%13.3%-13.5%1.391.35
5 years20.3%13.1%-17.4%1.010.99
10 years16.2%15.6%-23.4%0.590.57

Category rank: 2nd of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 97.0% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 10.55%
  2. Divi's Laboratories Limited — 8.38%
  3. Max Healthcare Institute Limited — 4.96%
  4. Acutaas Chemicals Limited — 4.95%
  5. Apollo Hospitals Enterprise Limited — 4.87%
  6. Laurus Labs Limited — 4.76%
  7. Cipla Limited — 4.36%
  8. TREPS (cash (TREPS)) — 4.14%
  9. Torrent Pharmaceuticals Limited — 4.11%
  10. Aurobindo Pharma Limited — 3.10%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.